Balantidiasis Market Research Report - Global forecast till 2023

Balantidiasis Market Research Report - Global forecast till 2023

ID: MRFR/HC/3303-HCRR | January, 2018 | Region: Global | 110 pages | Half-Cooked Research Reports

Balantidiasis Market Information: By Diagnosis (Physical Examination, Stool Examination, Sigmoidoscopy, Biopsy), By Treatment (Antibiotics, Appendectomy), By End User (Hospitals, Clinics, Diagnostic Centers)-Global Forecast Till 2023

FIGURE 1: Global Balantidiasis Market by Region, 2016 (%)

Balantidiasis Market


Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation


 


Intended Audience



  • Drug Manufacturers

  • Drug Suppliers

  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors




Research Methodology

Balantidiasis Market-


Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation


Market Synopsis of the Global Balantidiasis Market


Balantidiasis, also known as Balantidium coli infection, is a disease caused by intestinal protozoan parasite Balantidium coli.  Being transmitted through the fecal-oral route, a person acquires the disease by ingesting infective cysts from food and water contaminated by feces. The disease mainly affects large intestine. Diarrhea, weight loss, dysentery, abdominal pain, nausea, and vomiting are common symptoms for balantidiasis. The diseases is found to be prevalent in the rural areas of the developed and developing countries due to the contamination of water by the fecal matter of pigs or humans. The best remedy for the prevention of the disease are maintaining proper conditions for clean and safe drinking water. Antibiotics are most widely used for the treatment of balantidiasis.


Rising prevalence of gastrointestinal disorders, increasing number of patients and availability of treatment of balantidiasis drives the growth of the market. Additionally, the lack of hygiene and sanitation in the rural areas of developing countries is one of the many factors which affect the spread of this disease. Furthermore, rising awareness about the diseases transmitted through fecal-oral route influences the market growth. Competition among existing market players restrict the entry of new players.


The global balantidiasis market is expected to grow at a CAGR of 2.1% during the forecast period.


Segments                                                                                                                                            


The global balantidiasis market is segmented on the basis of diagnosis, treatment, and end user.


On the basis of diagnosis, the market is segmented into stool examination, sigmoidoscopy, biopsy, and others.


On the basis of treatment, the market is segmented into antibiotics, appendectomy, and others. Antibiotics segment is further divided into tetracycline, metronidazole, and others.


On the basis of end user, the market is segmented into hospitals, clinics, diagnostic centers, and others.


Regional Analysis of the Global Balantidiasis Market              


The market for balantidiasis is found to be steady in Americas. The disease is less prevalent in North America due to high quality standards, negligible number of cases, and hygienic environment. Furthermore, emphasis on healthy life style and prevention of communicable diseases also influence the growth of the market. The prevalence of the disease is found to the higher rural South America than North American countries.


In Europe, the prevalence of balantidiasis is found to be low. Rising importance of hygienic food products and water, rigorous quality checks, rising expenditure on healthcare, and availability of funds boost the growth of the market.


In Asia Pacific, the prevalence of balantidiasis is found increasing steadily as a result of increasing prevalence of colitis, chronic diarrhea, and, deep intestinal ulcerations and poor hygienic conditions in developing countries. The infection is found to be sub clinical leading to the development of diarrhea leading to the perforation of colon. Furthermore, poor healthcare system in developing countries boost the market growth. Furthermore, the burden of gastrointestinal diseases is attributed to an increase in age, high prevalence of H pylori and lifestyle changes with risk factors such as smoking and obesity. According to the data from GLOBOCAN, in 2012, the age-standardized rate (ASR) of incidence for Asia Pacific was 15.8 and mortality was 11.7 per 100,000. According to World Health Organization (WHO), the geriatric population in China in the year 2013 was 22.6 million which is expected to show a massive growth to 90.4 million in 2050.


The Middle East & African region has high prevalence of balantidiasis. The infection is mainly acquired due to ingestion of food and water contaminated by cysts. Furthermore, gastrointestinal diseases are a major cause of disability in the Middle East & Africa. In Africa, the market for balantidiasis is driven by rising demand for primary care services and improving healthcare system.


Key Players in the Global Balantidiasis Market


Some of the key players in this market are Pfizer (U.S.), Abbott (U.S.), GlaxoSmithKline plc. (U.K), BD (U.S.), Sandoz International GmbH (Germany), Amneal Pharmaceuticals LLC. (U.S.), Akorn, Inc. (U.S.), and PharmaDerm, a division of Fougera Pharmaceuticals Inc. (U.S.).

 Table of Content    

1.    Report Prologue    

2.    Market Introduction    


      2.1    Definition    

      2.2    Scope of the Study    

            2.2.1    Research Objective    

            2.2.2    Assumptions    

            2.2.3    Limitations    

3.    Research Methodology

      3.1    Introduction

      3.2    Primary Research    

      3.3    Secondary research    

      3.4    Market Size Estimation

4.    Market Dynamics

      4.1    Drivers    

      4.2    Restrains

      4.3    Opportunities    

      4.4    Challenges

      4.5    Macroeconomic Indicators

      4.6    Technology Trends & Assessment            

5.    Market Factor Analysis

      5.1    Porters Five Forces Analysis

            5.1.1    Bargaining Power of Suppliers    

            5.1.2    Bargaining Power of Buyers

            5.1.3    Threat of New Entrants    

            5.1.4    Threat of Substitutes    

            5.1.5    Intensity of Rivalry    

      5.2    Value Chain Analysis

      5.3    Investment Feasibility Analysis    

      5.4    Pricing Analysis

6.    Global Balantidiasis Market, by Diagnosis

     6.1    Introduction

      6.2    physical examination

            6.2.1    Market Estimates & Forecast, 2017-2023

      6.3    stool examination

            6.3.1    Market Estimates & Forecast, 2017-2023

      6.4    sigmoidoscopy

            6.4.1    Market Estimates & Forecast, 2017-2023

      6.5    biopsy

            6.4.1    Market Estimates & Forecast, 2017-2023

7.    Global Balantidiasis Market, by Treatment

     7.1    Introduction

      7.2    antibiotics

            7.2.1    Market Estimates & Forecast, 2017-2023

      7.3    Appendectomy

            7.3.1    Market Estimates & Forecast, 2017-2023

8.    Global Balantidiasis Market, by End User

      8.1    Introduction

      8.2    Hospitals

            8.2.1    Market Estimates & Forecast, 2017-2023

      8.3    Clinics

            8.3.1    Market Estimates & Forecast, 2017-2023

      8.4    Diagnostic Centers

            8.4.1    Market Estimates & Forecast, 2017-2023

9.    Global Balantidiasis Market, by Region

      9.1    Introduction

      9.2    Americas

            9.2.1    North America

                9.2.1.1    U.S.

                9.2.1.1    Canada

            9.2.2    South America

      9.3    Europe

            9.3.1    Western Europe

                9.3.1.1    Germany

                9.3.1.2    France

                9.3.1.3    U.K.

                9.3.1.4    Italy

                9.3.1.5    Spain

                9.3.1.6    Rest of Western Europe

            9.3.2    Eastern Europe

      9.4    Asia Pacific

            9.4.1    Japan

            9.4.2    China

            9.4.3    India

            9.4.4    Australia

            9.4.5    Republic of Korea

            9.4.6    Rest of Asia Pacific

      9.5    The Middle East & Africa

            9.5.1    United Arab Emirates

            9.5.2     Saudi Arabia

            9.5.3    Oman

            9.5.4    Kuwait

            9.5.5    Qatar

            9.5.6    Rest of the Middle East & Africa

10    Company Landscape    

      10.1    Introduction    

      10.2    Market Share Analysis    

      10.3    Key Development & Strategies    

            10.3.1    Key Developments    

11    Company Profiles    

      11.1    Pfizer

            11.1.1    Company Overview    

            11.1.2    Product Overview    

            11.1.3    Financials    

            11.1.4    SWOT Analysis    

      11.2    Abbott

            11.2.1    Company Overview    

            11.2.2    Product Overview    

            11.2.3    Financial Overview    

            11.2.4    Key Developments    

            11.2.5    SWOT Analysis    

      11.3    GlaxoSmithKline plc.    

            11.3.1    Company Overview    

            11.3.2    Product Overview    

            11.3.3    Financial Overview

            11.3.4    Key Development    

            11.3.5    SWOT Analysis    

      11.4     BD

            11.4.1    Company Overview    

            11.4.2    Product/Business Segment Overview    

            11.4.3    Financial Overview    

            11.4.4    Key Development    

            11.4.5    SWOT Analysis    

      11.5    Amneal Pharmaceuticals LLC.

            11.5.1    Company Overview    

            11.5.2    Product Overview    

            11.5.3    Financial overview    

            11.5.4    Key Developments    

      11.6    Akorn, Inc.

            11.6.1    Company Overview    

            11.6.2    Product Overview    

            11.6.3    Financial Overview    

            11.6.4    Key Developments    

      11.7    Sandoz International GmbH

            11.7.1    Overview    

            11.7.2    Product Overview    

            11.7.3    Financials    

            11.7.4    Key Developments    

            11.7.5    SWOT Analysis    

    11.8    Others

12    MRFR Conclusion    

      12.1    Key Findings    

            12.1.1    From CEO’s View Point    

            12.1.2    Unmet Needs of the Market    

      12.2    Key Companies to Watch    

      12.3    Prediction of Pharmaceutical Industry

13    Appendix

LIST OF TABLES

Table 1        Balantidiasis Industry Synopsis, 2017-2023

Table 2        Global Balantidiasis Market Estimates and Forecast, 2017-2023, (USD Million)

Table 3        Global Balantidiasis Market by Region, 2017-2023, (USD Million)

Table 4        Global Balantidiasis Market by Diagnosis, 2017-2023, (USD Million)

Table 5        Global Balantidiasis Market by Treatment, 2017-2023, (USD Million)

Table 6        Global Balantidiasis Market by End Users, 2017-2023, (USD Million)

Table 7        North America Balantidiasis Market by Diagnosis, 2017-2023, (USD Million)

Table 8        North America Balantidiasis Market by Treatment, 2017-2023, (USD Million)

Table 9        North America Balantidiasis Market by End Users, 2017-2023, (USD Million)

Table 10    U.S. Balantidiasis Market by Diagnosis, 2017-2023, (USD Million)

Table 11    US Balantidiasis Market by Treatment, 2017-2023, (USD Million)

Table 12    US Balantidiasis Market by End Users, 2017-2023, (USD Million)

Table 13    Canada Balantidiasis Market by Diagnosis, 2017-2023, (USD Million)

Table 14    Canada Balantidiasis Market by Treatment, 2017-2023, (USD Million)

Table 15    Canada Balantidiasis Market by End Users, 2017-2023, (USD Million)

Table 16    South America Balantidiasis Market by Diagnosis, 2017-2023, (USD Million)

Table 17    South America Balantidiasis Market by Treatment, 2017-2023, (USD Million)

Table 18    South America Balantidiasis Market by End Users, 2017-2023, (USD Million)

Table 19    Europe Balantidiasis Market by Diagnosis, 2017-2023, (USD Million)

Table 20    Europe Balantidiasis Market by Treatment, 2017-2023, (USD Million)

Table 21    Europe Balantidiasis Market by End Users, 2017-2023, (USD Million)

Table 22    Western Europe Balantidiasis Market by Diagnosis, 2017-2023, (USD Million)

Table 23    Western Europe Balantidiasis Market by Treatment, 2017-2023, (USD Million)

Table 24    Western Europe Balantidiasis Market by End Users, 2017-2023, (USD Million)

Table 25    Eastern Europe Balantidiasis Market by Diagnosis, 2017-2023, (USD Million)

Table 26    Eastern Europe Balantidiasis Market by Treatment, 2017-2023, (USD Million)

Table 27    Eastern Europe Balantidiasis Market by End Users, 2017-2023, (USD Million)

Table 28    Asia Pacific Balantidiasis Market by Diagnosis, 2017-2023, (USD Million)

Table 29    Asia Pacific Balantidiasis Market by Treatment, 2017-2023, (USD Million)

Table 30    Asia Pacific Balantidiasis Market by End Users, 2017-2023, (USD Million)

Table 31    Middle East & Africa Balantidiasis Market by Diagnosis, 2017-2023, (USD Million)

Table 32    Middle East & Africa Balantidiasis Market by Treatment, 2017-2023, (USD Million)

Table 33    Middle East & Africa Balantidiasis Market by End Users, 2017-2023, (USD Million)

LIST OF FIGURES

Figure 1    Research Process

Figure 2    Segmentation for Global Balantidiasis Market

Figure 3    Segmentation Market Dynamics for Balantidiasis Market

Figure 4    Global Balantidiasis Market Share, by Diagnosis 2016

Figure 5    Global Balantidiasis Market Share, by Treatment 2016

Figure 6    Global Balantidiasis Market Share, by End Users, 2016

Figure 7    Global Balantidiasis Market Share, by Region, 2016

Figure 8    North America Balantidiasis Market Share, by Country, 2016

Figure 9    Europe Balantidiasis Market Share, by Country, 2016

Figure 10    Asia Pacific Balantidiasis Market Share, by Country, 2016

Figure 11    Middle East & Africa Balantidiasis Market Share, by Country, 2016

Figure 12    Global Balantidiasis Market: Company Share Analysis, 2016 (%)

Figure 13    Pfizer: Key Financials

Figure 14    Pfizer: Segmental Revenue

Figure 16    Pfizer: Geographical Revenue

Figure 17    Abbott: Key Financials

Figure 18    Abbott: Segmental Revenue

Figure 19    Abbott: Geographical Revenue

Figure 20    GlaxoSmithKline plc: Key Financials

Figure 21    GlaxoSmithKline plc: Segmental Revenue

Figure 22    GlaxoSmithKline plc: Geographical Revenue

Figure 23    BD: Key Financials

Figure 24    BD: Segmental Revenue

Figure 25    BD: Geographical Revenue

Figure 26    Amneal Pharmaceuticals LLC..: Key Financials

Figure 27    Amneal Pharmaceuticals LLC: Segmental Revenue

Figure 28    Amneal Pharmaceuticals LLC: Geographical Revenue

Figure 29    Akorn, Inc.: Key Financials

Figure 30    Akorn, Inc.: Segmental Revenue

Figure 31    Akorn, Inc.: Geographical Revenue

Figure 32    Sandoz International GmbH: Key Financials

Figure 33    Sandoz International GmbH: Segmental Revenue

Figure 34    Sandoz International GmbH: Geographical Revenue